engleski

PD-L1 protein expression in NSCLC non-cell block cytology in correlation with patients clinical data

Aim: To compare the PD-L1 protein expression in NSCLC on various non-cell block cytology and patients clinical data. Materials and methods: Archive records of the clinical data and results of PD-L1 expression in patients with NSCLC over a period of one year. Materials were collected during bronchoscopy (bronchial washing/brushing and transbronchial fine needle aspirations), FNA of peripheral lymph nodes, skin nodules, transthoracic FNA/biopsy and pleural effusion. All materials were prepared as air dried non-cell block cytology slides and stained with Anti-PD-L1, Clone 22C3, Dako by Autostainer. PD-L1 protein expression was routinely examined and scored using Tumor Proportion Score(TPS) by two cytologists. Result: We have compared results of 341 patients out of 393 that underwent PD-L1 scoring. There were 216 smears of bronchoscopic material and 125 of various non bronchoscopic samples (FNA, PE, etc). PD-L1 was negative in total of 179/341 (52, 5%) samples. PD-L1 was positive in total of 162/341 (47, 5%) samples. Among PD-L1 positive, 105/162 were materials from bronchoscopy and 57/162 were obtained with others methods. PDL1 scored positive ≥ 50% in 72 samples, of which 45/72 (62, 5%) were bronchoscopic materials and 27/72(37, 5%) other materials. Comparison in PD-L1 expression between two groups of materials showed no statistical significant difference (x²test, df 1, p=.591). Comparison between two groups of PD-L1 positive ≥50% showed no statistical significant difference (x²test, df 1, p=.581). Among 341 included patients there were 210/341 (61, 6%) male and 131/341 (38, 4%) female. Most of the patients were in stage IV of disease 219/341 (64.2%) and older than 61 year 265/341 (77, 7%). The patients that were PD-L1 positive were in stage IV of disease in 95/162 (58, 6%) cases and most of them smoke 74/162(45, 7%) or were former smokers 59/162(36, 4%).Comparison of PD-L1 expression between gender (x²test, df 2, p=.55762.) smoking history(x²test, df 6, p=.59954.), stage of disease (x²test, df 8 p=.469207), and age (x²test, df 2, p=.834388.) show no statistical significant difference among groups. Out of 162 patients that were PD-L1 positive, 69 (42, 6%) received immunotherapy treatment. Conclusion:In our study there were no statistical significant differences in PD-L1 protein expression between different groups regarding gender, age, smoking status, stage of disease and material collecting method.

PD-L1 ; immunocytochemistry ; NSCLC ; non cell-block cytology

nije evidentirano